PENTAX-MEDICAL
PENTAX Europe GmbH has acquired the remaining stock of PENTAX Italia S.r.L. from Movi S.p.A. This further investment by PENTAX Europe GmbH into the Italian healthcare market strengthens PENTAX Medical’s position in Italy and will bring enhanced customer and professional education services to its Italian customers.
Established in 2007, PENTAX Italia was co-owned by PENTAX Europe GmbH and Movi S.p.A., an Italian distributor of healthcare products. PENTAX Italia has increased its sales of endoscopy products and services over this time, leading to PENTAX Europe GmbH’s decision to acquire full ownership.
Commenting on the acquisition, Rainer Burkard, Managing Director PENTAX Europe GmbH and President PENTAX Medical EMEA said: “Italy has been a strong market for PENTAX Medical and we are keen to continue our growth and bring our market leading products and services to as many customers in Italy as possible. To that end I am really pleased that PENTAX Italia will now be a wholly-owned subsidiary of PENTAX Medical, and thank Movi for its support and contribution to PENTAX Italia’s development.”
Adriano Tinelli, Managing Director PENTAX Italia S.r.L. said: “PENTAX Italia’s success has been built on a combination of both our innovative, high-performance endoscopy products and, importantly, our customer focus. We are very excited about how we can develop our customer experience and we look forward to strengthening our ability to bring our products and professional education services to clinicians throughout Italy.”
Enrico Piero Bassani, president of Movi S.p.A, commented: “PENTAX Italia has been a successful company for many years, thanks to the strong commitment of both shareholders that worked very positively together. The acquisition of our minority share by PENTAX Europe GmbH was a natural step for us and of course we wish PENTAX Italia to continue its development, to increase the market share, and keep a strong position in our important market.”
Details of the deal were not disclosed.
About PENTAX Medical
PENTAX Medical is a division of HOYA
Group. Its mission is to improve the standard of patient care and
quality of healthcare delivery by providing the best endoscopic products
and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION,
and SIMPLICITY. Through leading edge R&D and manufacturing, PENTAX
Medical provides endoscopic imaging devices and solutions to the global
medical community. Headquartered in Japan, PENTAX Medical has a
worldwide focus and presence with R&D, regional sales, service, and
in-country facilities around the globe.
For more information, please visit: www.pentaxmedical.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160121005366/en/
Contact:
Company enquiries
PENTAX Europe GmbH
Katharina
Meitzler, Marketing Communications EMEA
t: +49 40 561920
e: katharina.meitzler@pentaxmedical.com
w:
www.pentaxmedical.com
or
Media
enquiries
Alto Marketing Limited
Andrew Fellows,
Client Account Director - Healthcare
t: +44 (0)1489 557672
e: andrewf@alto-marketing.com
w:
www.alto-marketing.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CSG and NetLync Drive MNO and MVNO eSIM Transformation29.4.2025 09:30:00 CEST | Press release
Launch next-generation Entitlement SaaS platform that helps operators accelerate eSIM-only innovation and navigate the rapidly evolving telecom landscape With eSIM set to become the standard for all new phones this year,mobile network operators (MNOs) and mobile virtual network operators (MVNOs) face mounting pressure to modernize their entitlement infrastructure. To address this market need, CSG® (NASDAQ: CSGS) today announced a new partnership with leading entitlement server provider NetLync and launched CSG Entitlements-as-a-Service, powered by NetLync. This new SaaS platform gives operators the speed and agility they need to power seamless iOS and Android experiences in weeks, not months. It helps them stay competitive in an eSIM-only future and avoid the high costs of building and managing their own entitlement infrastructure. “The shift to eSIM-only devices drives a major change in the telecommunications industry that will redefine user experiences,” said Chad Dunavant, Chief Pro
SINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo Capital29.4.2025 09:29:00 CEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) issued a public letter to shareholders in response to hostile actions and false claims by Vivo Capital and certain other parties (the “Vivo group”) against the legitimate and lawful actions of the Board. Dear Shareholders, We are writing to set the record straight in response to the Vivo group’s recent press releases, lawsuits and other actions against SINOVAC and the Board, particularly those related to the Board’s decision to declare a cash dividend of US$55.00 per common share to SINOVAC shareholders. The Vivo group is now attempting to block the special dividend payments to you via lawsuits and by sending threatening letters and messages to the Company’s stock transfer agent and board members. It is particularly concerning that the Vivo group is trying to prevent all SINOVAC common shareholders (who hav
Suzano 2024 Annual Report on Form 20-F29.4.2025 09:29:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2024 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20250429838200/en/
KRAFTON Achieves Record-High Quarterly Sales in Q1 202529.4.2025 09:00:00 CEST | Press release
Thanks to PUBG IP expansion, inZOI’s strong debut, and BGMI’s global growth, quarter-over-quarter sales are up 41.6%, while operating profit is up 112.2% KRAFTON, Inc. today announced its first quarter earnings results for 2025. Based on consolidated financial statements prepared in accordance with Korean International Financial Reporting Standards (K-IFRS), the company achieved a record-high quarterly sales performance of 874.2B KRW and operating profit of 457.3B KRW. In addition to high quarter-over-quarter growth, year-over-year growth has also set records with sales up by 31.3% and operating profit upby 47.3%. Significant Growth and Core IP Direction KRAFTON achieved significant growth across all of its business divisions, including PC (323.5B KRW), mobile (532.4B KRW), and console/others (18.3B KRW). On PC platforms, PUBG: BATTLEGROUNDS’ diversified content and strong live-service operations contributed significantly to growth while the successful launch of a new IP, inZOI, also p
Azalea Vision Raises €9 Million in First Closing of Series A to Further Develop Intelligent Connected Vision Platform29.4.2025 09:00:00 CEST | Press release
Industry veteran Robert J. Dempsey Appointed Chairman of the Board to Guide Strategic Growth in Europe and the U.S. Azalea (A-zuh-lay-ah)Vision, a HealthTech company engineering the future of sight, today announced the first closing of its €15 million Series A funding round, raising €9 million along with the appointment of Robert J. Dempsey as Chairman of the Board to guide strategic growth in the European and U.S. markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429247873/en/ Robert Dempsey, Chairman of the Board, Azalea Vision "Strong participation from repeat investors in this Series A milestone reaffirms their trust in our medical device and innovation for the future of intelligent ocular health,” said Enrique Vega, CEO of Azalea Vision. “Additional funding in this round from SPRIM Global Investments and Afrimobility, along with a strategic investor who remains undisclosed, further emphasizes the confidence in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom